ContraFect Corporation announces the first patient has been dosed in the Phase 1b/2 of exebacase in the setting of an arthroscopic debridement, antibiotics, irrigation, and retention procedure in patients with chronic prosthetic joint infections of the knee due to Staphylococcus aureus or Coagulase-Negative Staphylococci. "We are pleased by the rapid enrollment of the first patient in our PJI study of exebacase," said Roger Pomerantz, MD, President, Chief Executive Officer, and Chairman of ContraFect. "It is important to understand that surgical revision of the infected prosthesis, the current standard of care for chronic PJI, has barely improved clinical outcomes over the past several decades. We believe exebacase has the potential to replace this debilitating and expensive surgical procedure, eradicate the infection, and significantly improve quality of life for patients with chronic PJIs suffering from pain and loss of mobility."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CFRX:
- ContraFect Data Presentations at the 33rd Annual ECCMID Meeting Highlight the Potential Efficacy of Lysin CF-370 Against Antibiotic Resistant Gram-negative Pathogens
- ContraFect presents CF-370 data at annual EECMID meeting
- Biotech Alert: Searches spiking for these stocks today
- ContraFect upgraded to Buy from Hold at Maxim
- ContraFect Announces Multiple Presentations of New Data at the 33rd Annual ECCMID Meeting